Pharmaceutical formulations for reducing pain
US7833973B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2009 |
| Grant date | Nov 16, 2010 |
| Priority date | — |
| Expiry date | Jun 12, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/43504
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.